


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
576B

In Re Application Of: **OETTEL, M., ET AL**

Serial No.  
10/729,487

Filing Date  
12/05/2003



Examiner

Group Art Unit

Title: **PHARMACEUTICAL PREPARATIONS FOR TREATING SIDE EFFECTS...**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
576B

In Re Application: **OETTEL, M., ET AL**

Serial No.  
10/729,487

Filing Date  
12/05/2003



Examiner

Group Art Unit

**PHARMACEUTICAL PREPARATIONS FOR TREATING SIDE EFFECTS...**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account as described below.
- ☐ Charge the amount of \_\_\_\_\_
  - ☐ Credit any overpayment.
  - ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_

(Date)

*Signature*

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on **APRIL 26, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Signature of Person Mailing Correspondence*

**MICHAEL J. STRIKER**


*Typed or Printed Name of Person Mailing Certificate*

**\*This certificate may only be used if paying by deposit account.**

*Signature*

Dated: **APRIL 26, 2004**

CC:



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:.

Group:

Attorney Docket # 576B

Applicant(s): OETTEL, M., ET AL

Serial No.: 10/729,487

Filed: 12/05/2003

For : PHARMACEUTICAL PREPARATIONS FOR  
TREATING SIDE EFFECTS...

**INFORMATION DISCLOSURE STATEMENT**

April 26, 2004

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

S I R S:

\_\_\_\_\_ In accordance with the Duty of Disclosure, Applicant(s) submit(s) herewith a copy of a Foreign Search Report in a counterpart application and copies of the reference(s) indicated therein.

\_\_\_\_\_ In the event that the Foreign Search Report is in a foreign language, a translation thereof is herewith submitted.

\_\_\_X\_\_\_ Attached hereto is a FORM PTO 1449 listing the references.

\_\_\_\_\_ Attached hereto is a copy of a reference cited in the specification of the application as filed. The specification itself recites the relevance of these documents, and pursuant to M.P.E.P. Section 609 A (3) this represents an acceptable Statement of Relevancy. The reference(s) appear(s) at the following page(s) and line(s) of the specification:

\_\_\_\_\_ Applicant petitions for consideration of this Information Disclosure Statement since it is being submitted after receipt of an office action. It is respectfully requested that the required fee be charged to the account of the undersigned: 19-4675.

page 2 of 2

☒ Attached hereto are copies of references cited which may be pertinent to this application. Since the references are in the English language, no statement of relevancy is submitted.


☐ Attached hereto is a copy of the Office Action issued in the corresponding German and European applications, together with a translation thereof and copies of the references cited therein. A list of the cited references is also attached.

☐ Attached hereto copies of references cited which may be pertinent to this application. A Certified English translation of the reference is also attached.


☐ Attached hereto is a Statement of Relevancy and copies of references cited therein.

☐ Relevancy is indicated in an English language abstract attached hereto.

Respectfully submitted,

  
Michael J. Striker  
Attorney for Applicant(s)  
Reg. No. 27233

*(Use several sheets if necessary)*



576B

**10/729,487**

OETTEL, M., ET AL

**12/05/2003**

GROUP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		97/21704	06/19/1997	WO			✓	
		91/14704	10/03/1991	WO			✓	
		94/26207	11/24/1994	WO			✓	
		0 402 950 A2	12/19/1990	EP			✓	
		91/01748	02/21/1991	WO			✓	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

			RENE WEZL ET AL: "WIRKSAMKEIT UND VERTRAEGLICHKEIT EINES GONADOTROPIN..." WIEN KLIN WOCHENSCHR, 1999, 111/7, PP. 283-288, SPRINGER VERLAG 1999.
			ERIC S. SURREY : "STEROIDAL AND NONSTROIDAL "ADD-BACK"..." FERTILITY AND STERILITY, VOL. 64, NO. 4, OCTOBER 1995, PP. 673-685.

**EXAMINER**

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# **INFORMATION DISCLOSURE CITATION**

*(Use several sheets if necessary)*

ATTY DOCKET NO.

**576B**

SERIAL NO.

**10/729,487**

APPLICANT(S)

**OETTEL, M., ET AL**

FILING DATE

**12/05/2003**

GROUP

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## **OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

			<b>G. FREUNDL: "STEROIDAL "ADD-BACK" THERAPY IN PATIENTS TREATED WITH..." GYNECOL OBSTET INVEST 1998, 45 (SUPPL 1) PP. 22-30.</b>
			<b>L. ANTILA, ET AL: "GNRH AGONISTS: CLINICAL APPLICATION..." ARTA 1997, VOL. 9, PP. 65-74.</b>

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY DOCKET NO.

**576B**

SERIAL NO.

**10/729,487**

APPLICANT(S)

**OETTEL, M., ET AL**

FILING DATE

**12/05/2003**

GROUP

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## **OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

			<b>BARBARA B. SHERWIN ET AL: "ADD-BACK" ESTROGEN REVERSES COGNITIVE DEFICITS..." JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, VOL. 81, NO. 7, PP. 2545-2549.</b>
			<b>J. S. HEINER, ET AL: "COMPARISON OF A GONADOTROPIN-RELEASING HORMONE..." JOURNAL OF ENDOCRINOLOGY AND METABOLISM, VOL. 80, NO. 12, PP. 3412-3418.</b>

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.